Management of immune-related cutaneous adverse events associated with immune checkpoint inhibitors in patients with cancer: an evidence summary.
BMJ OpenSep 23, 2026 (epub)
Qi Zhang, Shenting Cheng, Shouqi Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review synthesizes evidence on managing immune-related cutaneous adverse events (ircAEs) in cancer patients receiving immune checkpoint inhibitors (ICIs). It includes 21 evidence sources and provides 29 evidence statements across various domains, emphasizing the importance of early recognition and standardized management protocols for ircAEs.
Key findings
- 29 evidence statements were synthesized across seven domains related to ircAEs management.
- Emphasis on baseline skin assessment and early recognition of ircAEs was highlighted.
- Structured follow-up and patient education were identified as critical components of management.
- Timely multidisciplinary referral is recommended for severe or complex cutaneous toxicities.
Why it matters
Understanding the management of ircAEs is crucial for clinicians treating cancer patients with ICIs, as effective management can improve patient outcomes and quality of life. Standardized protocols can enhance care delivery and ensure timely interventions.